Lyka Labs Limited (LYKALABS) Q2 FY27 Financial Results: PAT ₹210.01 Cr & Revenue ₹4,272.79 Cr

Investor Takeaways

• Consolidated net total income grew 26.95% YoY to ₹4,272.79 crores, driven by 68.03% export revenue growth and 15.91% domestic sales increase.
• Standalone net profit surged 159.04% to ₹210.01 crores, while consolidated net profit rose 105.44% to ₹204.66 crores.
• Consolidated EBITDA margin declined to 11.74% from 13.07% YoY, indicating margin pressure despite revenue growth.
• ⚠️ No specific risks identified in this filing.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

What Changed

The filing reveals a significant inflection point in Lyka Labs Limited's financial trajectory during Q1 FY27. Consolidated revenue expanded robustly by 26.95% YoY to ₹4,272.79 crores, propelled by strong export growth (68.03%) and healthy domestic sales expansion (15.91%). This top-line momentum translated into a substantial profit surge, with consolidated net profit increasing 105.44% to ₹204.66 crores and standalone net profit jumping 159.04% to ₹210.01 crores. However, this growth occurred alongside a notable contraction in consolidated EBITDA margin, which declined to 11.74% from 13.07% YoY, signaling emerging operational headwinds. The margin compression appears to be the primary concern, as it contrasts with the otherwise positive revenue and profit trends. The company's standalone financials show consistent profitability across quarters, with Q3FY25 OPM at 15.36% and standalone profit rising from ₹1.29 Cr in Q1FY25 to ₹2.7 Cr in Q3FY25. The current market cap of ₹206.22 Cr and P/E ratio of 52.05 reflect investor sentiment toward this growth phase, though the declining margin trajectory warrants close monitoring for sustainability.

Peer Comparison

Lyka Labs Limited's P/E ratio of 52.05 is positioned between Sun Pharmaceutical's 41.28 and Divi's Laboratories' 72.41, suggesting moderate valuation relative to peers. However, its market capitalization is significantly smaller than the established peers, reflecting its niche positioning in the pharmaceutical sector.

Risks & Concerns

• No specific risks identified in this filing.

Quarterly Trend